

**May 13, 2019**

The Manager  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400001

Dear Sir,

Scrip No. **539680**

**Sub: Outcome of the Board Meeting held today i.e. on May 13, 2019**

With regard to the captioned subject and in compliance with the Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. on May 13, 2019 (commenced at 3:00 p.m. and concluded at 4:00 p.m.) considered and approved the Audited Financial results for the half and financial year ended on March 31, 2019.

The Audited Financial Results as adopted and approved by the Board of Directors and Auditor's report thereon are attached herewith for your ready reference.

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified opinion for the half and Financial year ended on March 31, 2019.

Please take the same on your records and suitably disseminated at all concerned.

Thanking You,

Yours faithfully,  
For **Ganga Pharmaceuticals Limited**

  
**Bharat Sharma**  
Managing Director  
DIN: 00077026



Encl.: As above

**Regd. Office & Factory :** Gangatat, Dhanvantri Marg, Gopchar Pada, Virar (E), 401 305, (Mumbai) INDIA

Tel. : 84520 49222 / 99678 40111

e-mail : [gplvirar@gmail.com](mailto:gplvirar@gmail.com) / [gangapharmaltd@gmail.com](mailto:gangapharmaltd@gmail.com) • Website : [www.ayurvedganga.com](http://www.ayurvedganga.com)

CIN No. : L99999MH1989PLC053392

GST No. : 27AABCG3922H1ZS

(Amount in lac)

AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON MARCH 31, 2019

| Sr. No | Particulars  | Figures for the half year ended on |               |               | Financial year ended on | Financial year ended on |
|--------|--|------------------------------------|---------------|---------------|-------------------------|-------------------------|
|        |  | 31-03-2019                         | 30-09-18      | 31-03-18      | 31-03-2019              | 31-03-2018              |
|        |  | (Audited)                          | (Un-Audited)  | (Audited)     | (Audited)               | (Audited)               |
| 1      | <b>INCOME FROM OPERATIONS</b>  |                                    |               |               |                         |                         |
|        | (a) Revenue from operations  | 159.74                             | 176.52        | 194.56        | 336.26                  | 305.26                  |
|        | (b) Other Income   | 7.47                               | 6.92          | 7.35          | 14.39                   | 14.61                   |
|        | <b>Total Income</b>  | <b>167.21</b>                      | <b>183.44</b> | <b>201.91</b> | <b>350.65</b>           | <b>319.87</b>           |
| 2      | <b>Expenses:</b>   |                                    |               |               |                         |                         |
|        | (a) Cost of Materials consumed   | 35.77                              | 88.80         | 83.75         | 124.57                  | 118.00                  |
|        | (b) Purchase of stock in trade   | -                                  | -             | -             | -                       | -                       |
|        | (c) Change in inventories of finished, WIP and stock in trade          | 22.55                              | (23.73)       | 1.82          | (1.17)                  | (2.08)                  |
|        | (d) Employee Benefit Expenses  | 21.58                              | 22.94         | 32.25         | 44.52                   | 43.57                   |
|        | (e) Finance Cost   | 12.84                              | 12.29         | 13.57         | 25.13                   | 27.76                   |
|        | (f) Depreciation and Amortization Expense                              | 1.53                               | 3.76          | 3.73          | 5.29                    | 5.87                    |
|        | (g) Other Administrative Expenses                                      | 67.13                              | 59.34         | 55.50         | 126.47                  | 114.08                  |
|        | <b>Total Expenses</b>  | <b>161.40</b>                      | <b>163.40</b> | <b>190.62</b> | <b>324.80</b>           | <b>307.21</b>           |
| 3      | <b>Profit/(Loss) before Tax (1-2)</b>                                  | <b>5.81</b>                        | <b>20.04</b>  | <b>11.28</b>  | <b>25.85</b>            | <b>12.66</b>            |
| 4      | <b>Tax Expenses</b>  |                                    |               |               |                         |                         |
|        | (a) Current Tax  | 1.47                               | 5.16          | 2.76          | 6.63                    | 3.17                    |
| =      | (b) Deffered Tax   | 0.50                               | 0.00          | 0.05          | 0.50                    | 0.09                    |
| 5      | <b>Net Profit / (Loss) for the period (3-4)</b>                        | <b>3.84</b>                        | <b>14.88</b>  | <b>8.47</b>   | <b>18.71</b>            | <b>9.39</b>             |
| 6      | <b>Other Comprehensive Income</b>                                      | -                                  | -             | -             | -                       | -                       |
| 7      | <b>Paid - Up equity share capital ( Equity Share of Rs. 10/- each)</b> | <b>406.15</b>                      | <b>406.15</b> | <b>406.15</b> | <b>406.15</b>           | <b>406.15</b>           |
| 8      | <b>Earning per equity share (Rs.)</b>                                  |                                    |               |               |                         |                         |
|        | (1) Basic  | 0.09                               | 0.37          | 0.21          | 0.46                    | 0.23                    |
|        | (2) Diluted  | 0.09                               | 0.37          | 0.21          | 0.46                    | 0.23                    |

Notes:

- The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on May 13, 2019.
- The figures for the half year ended on March 31, 2019 has been reviewed by the statutory Auditors' of the Company.
- As the Company ' business activities falls within a single segment, the disclosure requirement of the Accounting standard AS(17) " Segment Reporting" as notified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules 2014 are not applicable.
- The figures for the corresponding previous period have been regrouped /reclassified wherever considered necessary to confirm the figures in the current period.

For and on behalf of the Board of Directors  
Ganga Pharmaceuticals Limited

  
Bharat Sharma  
Managing Director  
DIN : 00077026



Place: Virar, Palghar  
Date : 13 May, 2019



GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305

Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Assests and Liabilities as at 31st March 2019

(Amount in Rs)

| Statement of Assets and Liabilities Particulars |                                    | As at<br>(31-03-2019) | As at<br>(31-03-2018) |
|---|------------------------------------|-----------------------|-----------------------|
| <b>A</b>  | <b>EQUITY AND LIABILITIES</b>      |                       |                       |
|   | <b>(1) Shareholders Funds:</b>     |                       |                       |
|   | (a) Share Capital                  | 4,06,15,000           | 4,06,15,000           |
|   | (b) Reserve & Surplus              | 1,09,20,883           | 90,85,264             |
|   | <b>(2) Non-Current Liabilities</b> |                       |                       |
|   | (a) Long-Term Borrowings           | 66,23,088             | 87,20,216             |
|   | (b) Deferred Tax Liabilities (Net) | 26,361                | -                     |
|   | (c) Other Long Term Liabilities    | -                     | -                     |
|   | (d) Long Term Provisions           | -                     | -                     |
|   | <b>(3) Current Liabilities</b>     |                       |                       |
|   | (a) Short-term borrowings          | 1,21,07,034           | 1,17,66,977           |
|   | (b) Trade payables                 | 54,82,155             | 1,05,37,215           |
|   | (c) Other current liabilities      | 17,61,631             | 16,13,479             |
|   | (d) Short-term provisions          | 43,128                | -                     |
|   | <b>Total</b>                       | <b>7,75,79,280</b>    | <b>8,23,38,151</b>    |
| <b>B</b>  | <b>ASSETS</b>                      |                       |                       |
|   | <b>(1) Non - Current assets</b>    |                       |                       |
|   | (a) Fixed Assets                   | 80,18,721             | 82,23,592             |
|   | (b) Non-current investments        | 8,92,500              | 42,500                |
|   | (c) Deferred tax assets (net)      | -                     | 24,018                |
|   | (d) Long term loans and advances   | -                     | -                     |
|   | (e) Other Non-current assets       | 2,51,69,375           | 2,77,37,160           |
|   | <b>(2) Current assets</b>          |                       |                       |
|   | (a) Current Investment             | -                     | -                     |
|   | (b) Inventories                    | 1,15,38,090           | 1,14,21,421           |
|   | (c) Trade receivables              | 1,22,64,226           | 1,58,24,757           |
|   | (d) Cash and cash equivalents      | 23,65,357             | 29,05,867             |
|   | (e) Short-term loans and advances  | 1,21,93,208           | 2,00,000              |
|   | (f) Other current assets           | 51,37,803             | 1,59,58,836           |
|   | <b>Total</b>                       | <b>7,75,79,280</b>    | <b>8,23,38,151</b>    |

For and on behalf of the Board of Directors of  
Ganga Pharmaceuticals Limited

*Bharat Sharma*

Bharat Sharma  
Managing Director  
DIN : 00077026



Place: N Virar, Palghar

Date : 13 May, 2019

# Anil Bansal & Associates

## CHARTERED ACCOUNTANTS

1001, IJMIMA Complex,  
Raheja's Metroplex,  
Near Infinity Mall-II,  
Link Road, Malad (West),  
Mumbai - 400064.  
Phone : 67098000/01  
e-mail : anilbansal1001@gmail.com

### Auditor's Report on Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

To,  
The Board of Directors of  
Ganga Pharmaceuticals Limited

We have audited the accompanying financial results of **Ganga Pharmaceuticals Limited** for Half year ended 31<sup>st</sup> March 2019 and the year to date results for the period from 01.04.2018 to 31.03.2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

These Half yearly financial results as well as the year to the date financial results have been prepared on the basis of the related financial statements, which are the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting standards for interim financial reporting, prescribed, under Section 133 of the companies Act 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining on test basis evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these half yearly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 in this regards and
- (ii) give a true and fair view of the net profit and other financial information for the half year ended 31<sup>st</sup> March 2019 as well as the year to date results for the period from 01.04.2018 to 31.03.2019

For Anil Bansal & Associates  
Chartered Accounts  
(FRN.:100421W)



Anil Bansal  
Proprietor  
Membership No. 043918  
Place: Mumbai  
Date: 13<sup>th</sup> May, 2019